Molecular mechanisms of programmed cell death-1 dependent T cell suppression: relevance for immunotherapy

Simple item page
dc.contributor.authorZuazo Ibarra, Miren
dc.contributor.authorGato Cañas, María
dc.contributor.authorLlorente, Noelia
dc.contributor.authorIbañez Vea, María
dc.contributor.authorArasanz Esteban, Hugo
dc.contributor.authorKochan, Grazyna
dc.contributor.authorEscors Murugarren, David
dc.contributor.departmentCiencias de la Saludes_ES
dc.contributor.departmentOsasun Zientziakeu
dc.contributor.funderGobierno de Navarra / Nafarroako Gobernuaes
dc.date.accessioned2022-08-08T12:04:09Z
dc.date.available2022-08-08T12:04:09Z
dc.date.issued2017
dc.date.updated2022-08-08T11:05:22Z
dc.description.abstractProgrammed cell death-1 (PD1) has become a significant target for cancer immunotherapy. PD1 and its receptor programmed cell death 1 ligand 1 (PDL1) are key regulatory physiological immune checkpoints that maintain self-tolerance in the organism by regulating the degree of activation of T and B cells amongst other immune cell types. However, cancer cells take advantage of these immunosuppressive regulatory mechanisms to escape T and B cell-mediated immunity. PD1 engagement on T cells by PDL1 on the surface of cancer cells dramatically interferes with T cell activation and the acquisition of effector capacities. Interestingly, PD1-targeted therapies have demonstrated to be highly effective in rescuing T cell anti-tumor effector functions. Amongst these the use of anti-PD1/PDL1 monoclonal antibodies are particularly efficacious in human therapies. Furthermore, clinical findings with PD1/PDL1 blockers over several cancer types demonstrate clinical benefit. Despite the successful results, the molecular mechanisms by which PD1-targeted therapies rescue T cell functions still remain elusive. Therefore, it is a key issue to uncover the molecular pathways by which these therapies exert its function in T cells. A profound knowledge of PDL1/PD1 mechanisms will surely uncover a new array of targets susceptible of therapeutic intervention. Here, we provide an overview of the molecular events underlying PD1-dependent T cell suppression in cancer.en
dc.description.sponsorshipThe authors gratefully acknowledge the Gobierno de Navarra, the ‘Precipita’ crowdfunding project grant from Fundación Española para la Ciencia y la Tecnología (FECYT), ‘Sandra Ibarra’ Foundation, the ‘Navarrese Association against Breast Cancer’ (SARAY), ‘Caixa Foundation’ and ISCIII (FIS. PI14/00579 project grant) for their financial support. Funding: M Gato-Cañas is funded by a Government of Navarre PhD fellowship (BMED 033-2014); M Zuazo is funded by PhD studentship from the Universidad Pública de Navarra; M Ibañez-Vea is funded by a Sara Borrel post-doctoral fellowship. D Escors is funded by a ‘Miguel Servet’ Fellowship (CP12/03114) from the Instituto de Salud Carlos III (ISCIII), Spain. G Kochan is funded by a ‘Proyecto Tractor ProCel’ from the Government of Navarreen
dc.format.mimetypeapplication/pdfen
dc.identifier.citationZuazo, M.; Gato-Cañas, M.; Llorente, N.; Ibañez-Vea, M.; Arasanz, H.; Kochan, G.; Escors, D.. (2017). Molecular mechanisms of programmed cell death-1 dependent T cell suppression: relevance for immunotherapy. Annals of Translational Medicine. 5,19, pp. 385-391 .en
dc.identifier.doi10.21037/atm.2017.06.11
dc.identifier.issn2305-5839
dc.identifier.urihttps://academica-e.unavarra.es/handle/2454/43729
dc.language.isoengen
dc.publisherAME Publishingen
dc.relation.ispartofAnnals of Translational Medicine, 2017, 5 (19), pp. 385-391en
dc.relation.projectIDinfo:eu-repo/grantAgreement/MINECO//PI14%2F00579/ES/
dc.relation.publisherversionhttps://doi.org/10.21037/atm.2017.06.11
dc.rightsCreative Commons Attribution-NonCommercial-NoDerivatives 4.0 Internationalen
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectCanceren
dc.subjectImmune checkpoint inhibitorsen
dc.subjectImmunotherapyen
dc.titleMolecular mechanisms of programmed cell death-1 dependent T cell suppression: relevance for immunotherapyen
dc.typeinfo:eu-repo/semantics/article
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dspace.entity.typePublication
relation.isAuthorOfPublication193d800d-c38c-4627-b9d8-d29435d8214c
relation.isAuthorOfPublicationf96114c2-9fc5-4886-ab9a-4804f14aa9c6
relation.isAuthorOfPublication.latestForDiscovery193d800d-c38c-4627-b9d8-d29435d8214c

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Zuazo_MolecularMechanisms_1659954957967_41784.pdf
Size:
628.78 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.78 KB
Format:
Item-specific license agreed to upon submission
Description:
Download

Collections

Artículos de revista DCS - OZS Aldizkari artikuluak
Artículos de revista - Aldizkari artikuluak